141 related articles for article (PubMed ID: 12091216)
21. A patient with ectopic cortisol production derived from malignant testicular masses.
Jain SH; Sadow PM; Nosé V; Dluhy RG
Nat Clin Pract Endocrinol Metab; 2008 Dec; 4(12):695-700. PubMed ID: 18941436
[TBL] [Abstract][Full Text] [Related]
22. Metyrapone treatment in Cushing's syndrome: a real-life study.
Ceccato F; Zilio M; Barbot M; Albiger N; Antonelli G; Plebani M; Watutantrige-Fernando S; Sabbadin C; Boscaro M; Scaroni C
Endocrine; 2018 Dec; 62(3):701-711. PubMed ID: 30014438
[TBL] [Abstract][Full Text] [Related]
23. [2 cases of Cushing's syndrome successfully treated with bromocriptine].
Medraś M; Plamieniak Z; Bidzińska B
Pol Tyg Lek; 1988 Sep; 43(39):1263-5. PubMed ID: 2854251
[No Abstract] [Full Text] [Related]
24. Results of treatment in 108 patients with Cushing's syndrome.
Orth DN; Liddle GW
N Engl J Med; 1971 Jul; 285(5):243-7. PubMed ID: 4326256
[No Abstract] [Full Text] [Related]
25. Metyrapone in long-term management of Cushing's disease.
Jeffcoate WJ; Rees LH; Tomlin S; Jones AE; Edwards CR; Besser GM
Br Med J; 1977 Jul; 2(6081):215-7. PubMed ID: 195666
[TBL] [Abstract][Full Text] [Related]
26. [Use of cyproheptadine in the treatment of Cushing's disease].
Jannì A; Carmina E; Lanzara P; Lo Coco R; Longo RA
Clin Ter; 1979 Feb; 88(4):345-54. PubMed ID: 222530
[No Abstract] [Full Text] [Related]
27. Pregnancy-dependent Cushing's syndrome in three pregnancies.
Kasperlik-Zaluska AA; Szczupacka I; Leszczynska-Bystrzanowska J; Drus-Przybyszewska G
BJOG; 2000 Jun; 107(6):810-2. PubMed ID: 10847243
[No Abstract] [Full Text] [Related]
28. Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing's disease.
van den Bosch OF; Stades AM; Zelissen PM
Clin Endocrinol (Oxf); 2014 Feb; 80(2):184-90. PubMed ID: 23841642
[TBL] [Abstract][Full Text] [Related]
29. Cyproheptadine in the control of Cushing's disease.
Hsu TH; Gann DS; Tsan KW; Russell RP
Johns Hopkins Med J; 1981 Aug; 149(2):77-83. PubMed ID: 6265685
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of biological determination of A.C.T.H. with the clinical, biological and evolutive conditions in 10 cases of Cushing's syndrome].
de Gennes JL; Beauchef JP; Girard F; Decourt J
Ann Endocrinol (Paris); 1971; 32(6):835-44. PubMed ID: 4339010
[No Abstract] [Full Text] [Related]
31. [Behavior of adrenocorticotropic internal secretions in Cushing's syndrome].
Silvestrini F; D'Alonzo R
Schweiz Med Wochenschr; 1970 Oct; 100(40):1680-4. PubMed ID: 4335210
[No Abstract] [Full Text] [Related]
32. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.
Feelders RA; Hofland LJ; de Herder WW
Neuroendocrinology; 2010; 92 Suppl 1():111-5. PubMed ID: 20829630
[TBL] [Abstract][Full Text] [Related]
33. [Prolonged remission in Cushing's syndrome following treatment with ortho-para-dichlordiphenyldichlorethane].
Kirkegaard C; Kolendorf K
Ugeskr Laeger; 1974 Jun; 136(25):1389-91. PubMed ID: 4366485
[No Abstract] [Full Text] [Related]
34. Ketoconazole therapy in Cushing's disease.
Angeli A; Frairia R
Lancet; 1985 Apr; 1(8432):821. PubMed ID: 2858699
[No Abstract] [Full Text] [Related]
35. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
36. Cortisol measurement in patients receiving metyrapone therapy.
Owen LJ; Halsall DJ; Keevil BG
Ann Clin Biochem; 2010 Nov; 47(Pt 6):573-5. PubMed ID: 20926474
[TBL] [Abstract][Full Text] [Related]
37. Assessment of long-term efficacy and safety of metyrapone monotherapy in a patient with ACTH-independent macronodular adrenal hyperplasia.
Yoshida M; Umeda H; Iwama S; Nakayama S; Miyata M; Ogawa K; Maeda H; Oiso Y
Endocrine; 2012 Feb; 41(1):160-1. PubMed ID: 22038492
[No Abstract] [Full Text] [Related]
38. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.
Monaghan PJ; Owen LJ; Trainer PJ; Brabant G; Keevil BG; Darby D
Ann Clin Biochem; 2011 Sep; 48(Pt 5):441-6. PubMed ID: 21813575
[TBL] [Abstract][Full Text] [Related]
39. Cushing's syndrome caused by a metyrapone responsive adrenocortical adenoma.
Crystal RG; Rose LI; Jagger PI; Lauler DP
J Clin Endocrinol Metab; 1970 Aug; 31(2):199-203. PubMed ID: 4317343
[No Abstract] [Full Text] [Related]
40. Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.
Claps M; Cerri S; Grisanti S; Lazzari B; Ferrari V; Roca E; Perotti P; Terzolo M; Sigala S; Berruti A
Endocrine; 2018 Jul; 61(1):169-172. PubMed ID: 29019062
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
